These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
401 related articles for article (PubMed ID: 10589763)
1. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS. Masiakos PT; MacLaughlin DT; Maheswaran S; Teixeira J; Fuller AF; Shah PC; Kehas DJ; Kenneally MK; Dombkowski DM; Ha TU; Preffer FI; Donahoe PK Clin Cancer Res; 1999 Nov; 5(11):3488-99. PubMed ID: 10589763 [TBL] [Abstract][Full Text] [Related]
2. Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo. Pieretti-Vanmarcke R; Donahoe PK; Szotek P; Manganaro T; Lorenzen MK; Lorenzen J; Connolly DC; Halpern EF; MacLaughlin DT Clin Cancer Res; 2006 Mar; 12(5):1593-8. PubMed ID: 16533786 [TBL] [Abstract][Full Text] [Related]
3. Müllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers. Bakkum-Gamez JN; Aletti G; Lewis KA; Keeney GL; Thomas BM; Navarro-Teulon I; Cliby WA Gynecol Oncol; 2008 Jan; 108(1):141-8. PubMed ID: 17988723 [TBL] [Abstract][Full Text] [Related]
4. Identification of müllerian inhibiting substance specific binding in human cell lines. MacLaughlin DT; Levin RK; Catlin EA; Taylor LA; Preffer FI; Donahoe PK Horm Metab Res; 1992 Dec; 24(12):570-5. PubMed ID: 1478615 [TBL] [Abstract][Full Text] [Related]
5. Minimal antiproliferative effect of recombinant müllerian inhibiting substance on gynecological tumor cell lines and tumor explants. Wallen JW; Cate RL; Kiefer DM; Riemen MW; Martinez D; Hoffman RM; Donahoe PK; Von Hoff DD; Pepinsky B; Oliff A Cancer Res; 1989 Apr; 49(8):2005-11. PubMed ID: 2702642 [TBL] [Abstract][Full Text] [Related]
6. Highly purified müllerian inhibiting substance inhibits human ovarian cancer in vivo. Stephen AE; Pearsall LA; Christian BP; Donahoe PK; Vacanti JP; MacLaughlin DT Clin Cancer Res; 2002 Aug; 8(8):2640-6. PubMed ID: 12171896 [TBL] [Abstract][Full Text] [Related]
7. Human müllerian inhibiting substance inhibits tumor growth in vitro and in vivo. Chin TW; Parry RL; Donahoe PK Cancer Res; 1991 Apr; 51(8):2101-6. PubMed ID: 2009529 [TBL] [Abstract][Full Text] [Related]
8. YWK-II protein as a novel G(o)-coupled receptor for Müllerian inhibiting substance in cell survival. Yin X; Ouyang S; Xu W; Zhang X; Fok KL; Wong HY; Zhang J; Qiu X; Miao S; Chan HC; Wang L J Cell Sci; 2007 May; 120(Pt 9):1521-8. PubMed ID: 17452623 [TBL] [Abstract][Full Text] [Related]
9. Recombinant human mullerian inhibiting substance inhibits human ocular melanoma cell lines in vitro and in vivo. Parry RL; Chin TW; Epstein J; Hudson PL; Powell DM; Donahoe PK Cancer Res; 1992 Mar; 52(5):1182-6. PubMed ID: 1531323 [TBL] [Abstract][Full Text] [Related]
10. Müllerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Müllerian duct regression. Zhan Y; Fujino A; MacLaughlin DT; Manganaro TF; Szotek PP; Arango NA; Teixeira J; Donahoe PK Development; 2006 Jun; 133(12):2359-69. PubMed ID: 16687449 [TBL] [Abstract][Full Text] [Related]
11. Molecular biology of MIS and its receptors. Teixeira J; Donahoe PK J Androl; 1996; 17(4):336-41. PubMed ID: 8889695 [TBL] [Abstract][Full Text] [Related]
12. Identification of a receptor for human müllerian inhibiting substance. Catlin EA; Ezzell RM; Donahoe PK; Gustafson ML; Son EV; MacLaughlin DT Endocrinology; 1993 Dec; 133(6):3007-13. PubMed ID: 8243329 [TBL] [Abstract][Full Text] [Related]
13. Paracrine-mediated apoptosis in reproductive tract development. Roberts LM; Hirokawa Y; Nachtigal MW; Ingraham HA Dev Biol; 1999 Apr; 208(1):110-22. PubMed ID: 10075845 [TBL] [Abstract][Full Text] [Related]
14. Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer. Pieretti-Vanmarcke R; Donahoe PK; Pearsall LA; Dinulescu DM; Connolly DC; Halpern EF; Seiden MV; MacLaughlin DT Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17426-31. PubMed ID: 17088539 [TBL] [Abstract][Full Text] [Related]
15. Autocrine and paracrine Müllerian inhibiting substance hormone signaling in reproduction. Ingraham HA; Hirokawa Y; Roberts LM; Mellon SH; McGee E; Nachtigal MW; Visser JA Recent Prog Horm Res; 2000; 55():53-67; discussion 67-8. PubMed ID: 11036933 [TBL] [Abstract][Full Text] [Related]
16. Cleavage of Müllerian inhibiting substance activates antiproliferative effects in vivo. Kurian MS; de la Cuesta RS; Waneck GL; MacLaughlin DT; Manganaro TF; Donahoe PK Clin Cancer Res; 1995 Mar; 1(3):343-9. PubMed ID: 9815990 [TBL] [Abstract][Full Text] [Related]
17. The müllerian inhibitor and mammalian sexual development. Behringer RR Philos Trans R Soc Lond B Biol Sci; 1995 Nov; 350(1333):285-8; discussion 289. PubMed ID: 8570693 [TBL] [Abstract][Full Text] [Related]
19. Cytotoxic effects of müllerian inhibiting substance (MIS)? Janssens JP; Noto V; van Tendeloo G; Bonte J; de Loecker W Anticancer Res; 1988; 8(4):781-4. PubMed ID: 3178166 [TBL] [Abstract][Full Text] [Related]
20. Evidence for a Müllerian-inhibiting substance autocrine/paracrine system in adult human endometrium. Wang J; Dicken C; Lustbader JW; Tortoriello DV Fertil Steril; 2009 Apr; 91(4):1195-203. PubMed ID: 18328480 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]